This finding aligns with previous studies reporting FAT1 alterations in 39% of MF and PTCL cases, where they have been associated with more aggressive disease and poorer overall survival. This evidence concerns the gene FAT1 and mature T-cell and NK-cell non-Hodgkin lymphoma.